Suzhou Zelgen Biopharmaceuticals Co.,Ltd. (SHA: 688266)

Market Cap	17.71B
Revenue (ttm)	488.45M
Net Income (ttm)	-174.40M
Shares Out	264.71M
EPS (ttm)	-0.66
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,942,282
Open	62.77
Previous Close	62.44
Day's Range	61.70 - 64.00
52-Week Range	33.20 - 79.99
Beta	0.62
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 25, 2024

About Suzhou Zelgen Biopharmaceuticals Co.,Ltd.

Suzhou Zelgen Biopharmaceuticals Co.,Ltd. researches and develops, manufactures, and sells medicines in the People's Republic of China. It offers donafenib tablets; recombinant human thrombin for topincal use; jacktinib tablets; and recombinant human thyroid-stimulating hormone for injection; obeticholic acid magnesium tablets; ZG19018 tablets; ZG005 powder for injection; and alkotinib capsules for the treatment of liver cancer, non-small cell lung cancer, small cell lung cancer, colorectal cancer, thyroid cancer, and neuroendocrine cancer, as ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2009
• Employees: 867
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688266

Financial Performance

In 2023, Suzhou Zelgen Biopharmaceuticals Co.,Ltd.'s revenue was 386.44 million, an increase of 27.83% compared to the previous year's 302.31 million. Losses were -278.58 million, -39.08% less than in 2022.